Genzyme hires leaders for MS and rare diseases
This article was originally published in Scrip
Genzyme has appointed William Sibold head of multiple sclerosis and Rogério Vivaldi head of rare diseases. Both will report to David Meeker, Genzyme's president and CEO. Mr Sibold has over 20 years' experience in the biopharmaceutical industry, and has worked on MS products Avonex (interferon beta 1-a) and Tysabri (natalizumab). He most recently served as chief commercial officer at Avanir Pharmaceuticals. Mr Vivaldi joined Genzyme in 1997 and was previously president of the company's renal and endocrinology business.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.